Literature for rivaroxaban (S01.216 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2019
1. Qu,S.Y., Xu,Q., Wu,W., Li,F., Li,C.D., Huang,R., Ding,Q. and Wei,D.Q.
   An unexpected dynamic binding mode between coagulation factor X and rivaroxaban reveals importance of flexibility in drug binding
   Chem Biol Drug Des94, 1664-1671. PubMed  Europe PubMed DOI  I
2018
2. Horinaka,S., Sugawara,R., Yonezawa,Y. and Ishimitsu,T.
   Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
   Br J Clin Pharmacol84, 79-87. PubMed  Europe PubMed DOI  I
2013
3. King,C.S., Holley,A.B. and Moores,L.K.
   Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors
   Chest143, 1106-1116. PubMed  Europe PubMed DOI  I
2012
4. Becattini,C., Lignani,A. and Agnelli,G.
   New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors
   Curr Drug Discov Technol9, 119-128. PubMed  Europe PubMed  I
2009
5. Wong,P.C., Crain,E.J., Watson,C.A. and Xin,B.
   Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits
   J Thromb Haemost7, 1313-1320. PubMed  Europe PubMed DOI  I
6. Zikria,J.C. and Ansell,J.
   Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change
   Curr Opin Hematol16, 347-356. PubMed  Europe PubMed DOI  I
2007
7. Graff,J., von Hentig,N., Misselwitz,F., Kubitza,D., Becka,M., Breddin,H.K. and Harder,S.
   Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
   J Clin Pharmacol47, 1398-1407. PubMed  Europe PubMed DOI  I